TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03337594
Drug: Pre-operative MRI with MultiHance
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MultiHance® (gadobenate dimeglumine - Bracco)
Study: NCT00199329
Drug: ondansetron adding in PCA
Normalized name: lauryl PCA
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00392522
Drug: 50% Nitrous Oxide and 50% Oxygen (MEOPA)
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00943176
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
Study: NCT02143830
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity.
Study: NCT02143830
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
Study: NCT02143830
Drug: rabbit ATG
Normalized name: Rabbit ATG
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.
Study: NCT02143830
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will also receive G-CSF post-transplant to foster engraftment.
Study: NCT00191425
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00191425
Drug: Raloxifene
Normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00134641
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01359059
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
Study: NCT00134641
Drug: vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03488225
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT or IV
Study: NCT03488225
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT03488225
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03488225
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04405622
Drug: Toripalimab plus gemcitabine
Normalized name: Toripalimab
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects receive gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21 days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) maintenance. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
Study: NCT03619824
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200mg ivdrip, every 3 weeks for 6 cycles
Study: NCT03619824
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
Study: NCT03619824
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
Study: NCT00150852
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01701089
Drug: 11C-L-deprenyl-D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total
Study: NCT00038896
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02861417
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02861417
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02861417
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01245998
Drug: Dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dalteparin 5000 I.U./24 h s.c. for 6 weeks
Study: NCT02861417
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02861417
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT01245998
Drug: Dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dalteparin 15000 I.U./24 h s.c. for 6 weeks
Study: NCT02652455
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants entering the study after the first 6 participants only: Treatment with nivolumab prior to removal of tumor sample for TIL growth. About 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
Study: NCT02652455
Drug: CD137
Normalized name: Dna (synthetic human adenovirus 5/35 vector load703 human cd137 ligand and trimerized membrane-bound isoleucine zipper-containing human cd40 ligand-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants: Anti-CD137 agonistic antibody as an agent to augment T cell proliferation in vitro. The growth of the TIL will be accelerated by the use of CD137 activating antibody in the laboratory.
Study: NCT02861417
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00374218
Drug: High Fructose Corn Syrup
Normalized name: High Fructose Corn Syrup
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01674348
Drug: P2202
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties, being developed for the management of type 2 diabetes mellitus
Study: NCT02217280
Drug: Injection with Gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadavist (gadobutrol) injection is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system
Study: NCT02652455
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants: Lymphodepleting chemotherapy intravenously, beginning after first 2 days of cyclophosphamide.
Study: NCT01733459
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 Metformin XR caplet 750 mg twice daily for 6 months
Study: NCT01733459
Drug: Placebo caplet of Metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 placebo caplet of Metformin XR twice daily for 6 months
Study: NCT00509548
Drug: TG100801
DrugBank: G100 (DB17244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop, twice a day, 30 days.
Study: NCT02652455
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After TIL infusion, in-patient high dose IL-2 treatment.
Study: NCT04575259
Drug: ANAVEX2-73
Normalized name: ANAVEX2-73
DrugBank: Blarcamesine (DB05592)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT00299559
Drug: smart textiles containing menthol, camphor, cineol
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: application to skin
Study: NCT00504959
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01139463
Drug: Haloperidol or olanzapine
Normalized name: Haloperidol
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol tablet - 5 mg twice daily (morning and evening) by mouth Olanzapine tablet - 5 mg twice daily (morning and evening) by mouth
Study: NCT03009682
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosage and Schedule : Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days.~Two x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water. The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib can be taken with a light meal/snack.
Study: NCT02054000
Drug: Tirofiban
Normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administering of Tirofiban
Study: NCT04603794
Drug: 0.5% Povidone Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially Available Mouth Rinses and Over the Counter Standard Formulations
Study: NCT04603794
Drug: 0.12% Chlorhexidine Gluconate Mouth Rinse
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially Available Mouth Rinses
Study: NCT04603794
Drug: 1% Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
Study: NCT04105894
Drug: medical treatment of GERD t
Normalized name: coal tar Medicated Shampoo [Ionil T]
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical treatment of GERD only for 2 months as described by gastroenterology department
Study: NCT02317770
Drug: Lidocaine Spray
Normalized name: lidocaine Mucosal Spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 puffs of 10% Lidocaine spray is administered every 5 minutes for 4 times. Then the patient is undergone procedure 5 minutes later.
Study: NCT02317770
Drug: Nebulized Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient receives 2.5 mL of 10% lidocaine is used by nebulizer under oxygen flow 6-7 LPM for 15 minutes prior the procedure.
Study: NCT01259375
Drug: Amrubicin
Normalized name: amrubicin
DrugBank: Amrubicin (DB06263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously
Study: NCT03186989
Drug: IONIS MAPTRx
Normalized name: IONIS SOD1Rx
DrugBank: Tofersen (DB14782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: IONIS MAPTRx is administered intrathecally at 4 week intervals over the course of a 13 week treatment period for dose levels A, B, C, and D.~Part 2: IONIS MAPTRx is administered intrathecally at quarterly intervals for 48 weeks.
Study: NCT02698644
Drug: Isoamyl-2-cyanoacrylate
DrugBank: Amyl acetate (DB15927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
Study: NCT00002644
Drug: Tamoxifen Citrate 20Mg Tab
Normalized name: TAMOXIFEN CITRATE 20MG TAB
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen Citrate 20Mg Tab
Study: NCT00022490
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycle
Study: NCT01928316
Drug: Mizolastine domestic (made in China)
Normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy male volunteers will receive 10 mg domestic (made in China) mizolastine tablets on Day 1 and Day 8
Study: NCT00022490
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.
Study: NCT01485809
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib 250mg/day, oral daily q every 4 weeks
Study: NCT01670877
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01670877
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01670877
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00728013
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients are randomly assigned (1:1 ratio) by center to intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
Study: NCT00728013
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients are randomly assigned (1:1 ratio) by center to moderate therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins).
Study: NCT00982527
Drug: Fenoldopam
Normalized name: Fenoldopam
DrugBank: Fenoldopam (DB00800)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
Study: NCT01928316
Drug: Mizolastine (imported)
Normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy male volunteers will receive 10 mg imported mizolastine tablets on Day 1 and Day 8
Study: NCT00070642
Drug: dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dacarbazine 850mg/m2 in three-week cycles until disease progression
Study: NCT00496405
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00947024
Drug: 10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00947024
Drug: 10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01580839
Drug: Tissue Plasminogen Activator (Alteplase)
Normalized name: Tissue plasminogen activator alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
Study: NCT00648466
Drug: Sumatriptan Succinate Tablets 100 mg
Normalized name: Sumatriptan Succinate
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg, single dose fasting
Study: NCT03124121
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A biologic agent which acts by antagonising the effects of tumour necrosis factor (TNF) alpha
Study: NCT00189319
Drug: Flecainide controlled release
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00771511
Drug: capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsaicin cream 0.1% 10 ml applied to cervix
Study: NCT03262389
Drug: Fludeoxyglucose PET CT
Normalized name: Pet-ema
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
Study: NCT03262389
Drug: Sodium Acetate C11 PET CT
Normalized name: Choline C11
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
Study: NCT03262389
Drug: Fludeoxyglucose PET MRI
Normalized name: Pet-ema
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
Study: NCT03262389
Drug: Sodium Acetate C11 PET MRI
Normalized name: Choline C11
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
Study: NCT02418065
Drug: n3 polyunsaturated fatty acid
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01595425
Drug: D961H Sachet 20 mg
Normalized name: fosfomycin
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.
Study: NCT00006305
Drug: Biguanides, thiazolidinediones
DrugBank: Biguanide (DB13100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biguanides, thiazolidinediones
Study: NCT00547456
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxygen 2-3L Nasal cannula
Study: NCT01543204
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by subcutaneous injection
Study: NCT02817360
Drug: RAS-antagonist and beta-blocker up-to maximal dosages
Normalized name: ivermectin
DrugBank: Sage (DB10982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Patients receive a prescription and/or up-titration to maximum recommended or tolerated dose of RAS-antagonist and beta-blockers within three months of study entry. The Number of titration visits is up to the treating physician, but one visit should be performed at least at the end of titration.
Study: NCT01236950
Drug: Essential oils mouthrinse
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial mouthrinse with manufacturer's use indication
Study: NCT00113529
Drug: Gefitinib + Sunitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Until disease progression or unacceptable toxicity.
Study: NCT03066986
Drug: Delta-inulin
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Addition of adjuvant, delta-inulin to JJA VIT regime, to determine if this will allow lower doses and shorter regimes to promote protective responses, reducing costs and morbidity of JJA VIT.
Study: NCT03608046
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab will be administered at a fixed dose of 10 mg/kg once every 2- week
Study: NCT03608046
Drug: Cetuximab Injection
Normalized name: cetuximab Injection
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab will be administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3 and irinotecan administered every 2 weeks (180 mg/m2).
Study: NCT03608046
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan will be administered every 2 weeks (180 mg/m2)
Study: NCT03760263
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunosuppressive drug that can prevent organ rejection after transplant in its oral form.
Study: NCT00662558
Drug: tramadol HCL
Normalized name: tramadol HCl
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg capsules QID for 6 weeks
Study: NCT02999724
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 300-600 mg 1 hour preop
Study: NCT03042416
Drug: 18F-DOPA
Normalized name: (-)-dopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 18F-DOPA intravenous injection single dose
Study: NCT00047216
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no